{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2484780_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"172-545-014-439-83X"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10731,"type":"PATENT","title":"The University of North Carolina at Chapel Hill - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8887,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8232,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"uni* north caro*\". Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1000
Search Applicants and Owners separately:\"uni* north caro*\". Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1000
determining a genotype of the subject with respect to a gene selected from the group consisting of ADRB2, ADRB3, COMT, and combinations thereof,
wherein when the susceptibility of a subject to develop a somatosensory disorder is predicted,
the genotype comprises multiple polymorphisms that define haplotypes of the subject with respect to said gene, and the method further comprises:comparing the genotype of the subject with at least one reference genotype comprising multiple polymorphisms that define haplotypes associated with susceptibility to develop the somatosensory disorder, wherein the reference genotype is selected from the group consisting of an ADRB2 genotype, an ADRB3 genotype, a COMT genotype, and combinations thereof, whereby susceptibility of the subject to develop the somatosensory disorder is predicted; and
wherein when a therapy is selected for a subject having a somatosensory disorder, the therapy is selected based on the determined genotype of the subject."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the susceptibility of a subject to develop a somatosensory disorder is predicted."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein determining the genotype of the subject comprises
(i) identifying at least one haplotype of ADRB2, ADRB3, COMT or combinations thereof;
(ii) identifying at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof;
(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one ADRB2 haplotype, ADRB3 haplotype, COMT haplotype, or combinations thereof; or
(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one ADRB2 haplotype, ADRB3 haplotype, COMT haplotype, or combinations thereof."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the ADRB2 genotype of the reference genotype is selected from the group consisting of Haplotype 1, Haplotype 2, Haplotype 3, and Uncommon; the ADRB3 genotype of the reference genotype is selected from the group consisting of Haplotype 1, Haplotype 2, Haplotype 3, and Uncommon; and the COMT genotype of the reference genotype is selected from the group consisting of low pain sensitive haplotype (LPS), average pain sensitive haplotype (APS), and high pain sensitive haplotype (HPS), preferably wherein the determined genotype of the subject with respect to ADRB2 is selected from the group consisting of two copies of Haplotype 1, two copies of Haplotype 2, two copies of Haplotype 3, one copy of both Haplotype 2 and Haplotype 3, and at least one copy of Uncommon and the subject is predicted to be susceptible to develop the somatosensory disorder, further preferably wherein the determined genotype of the subject with respect to ADRB3 is selected from the group consisting of two copies of Haplotype 1, and at least one copy of Uncommon and the subject is predicted to be susceptible to develop the somatosensory disorder, and further preferably wherein the determined genotype of the subject with respect to COMT is selected from the group consisting of two copies of APS, two copies of HPS, and one copy of both APS and HPS and the subject is predicted to be susceptible to develop the somatosensory disorder, wherein the somatosensory disorder is preferably selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, and angina pectoris."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein a therapy is selected for a subject having a somatosensory disorder."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein determining the genotype of the subject comprises:
(i) identifying at least one haplotype of ADRB2, ADRB3, COMT or combinations thereof;
(ii) identifying at least one polymorphism unique to at least one haplotype of ADRB2, ADRB3, COMT, or combinations thereof;
(iii) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one polymorphism unique to at least one ADRB2 haplotype, ADRB3 haplotype, COMT haplotype, or combinations thereof; or
(iv) identifying at least one polymorphism exhibiting high linkage disequilibrium to at least one ADRB2 haplotype, ADRB3 haplotype, COMT haplotype, or combinations thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 6, wherein the ADRB2 genotype of the reference genotype is selected from the group consisting of Haplotype 1, Haplotype 2, Haplotype 3, and Uncommon; the ADRB3 genotype of the reference genotype is selected from the group consisting of Haplotype 1, Haplotype 2, Haplotype 3, and Uncommon; and the COMT genotype of the reference genotype is selected from the group consisting of low pain sensitive haplotype (LPS), average pain sensitive haplotype (APS), and high pain sensitive haplotype (HPS)."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 7, wherein the therapy is selected from the group consisting of a pharmacological therapy, a behavioral therapy, a psychotherapy, a surgical therapy, and combinations thereof."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 8, wherein the therapy is a pharmacological therapy comprising administering to the subject an effective amount of an ADRB2 antagonist, an ADRB3 antagonist, a COMT activator, or combinations thereof."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 9, wherein the determined genotype of the subject with respect to ADRB2 is selected from the group consisting of two copies of Haplotype 2, two copies of Haplotype 3,one copy of both Haplotype 2 and Haplotype 3, and an effective amount of an ADRB2 antagonist, a COMT activator, or combinations thereof is selected as a therapy, preferably wherein the determined genotype of the subject with respect to ADRB3 is two copies of Haplotype 1, and an effective amount of an ADRB2 antagonist, a COMT activator, or combinations thereof is selected as a therapy, further preferably wherein the determined genotype of the subject with respect to COMT is selected from the group consisting of two copies of APS, two copies of HPS, and one copy of both APS and HPS and an effective amount of an ADRB2 antagonist, an ADRB3 antagonist, a COMT activator, or combinations thereof is selected as a therapy."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 9, wherein both the ADRB2 antagonist and the ADRB3 antagonist are selected."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 5, wherein the somatosensory disorder is selected from the group consisting of chronic pain conditions, fibromyalgia syndrome, tension headache, migraine headache, phantom limb sensations, irritable bowel syndrome, chronic lower back pain, chronic fatigue, multiple chemical sensitivities, temporomandibular joint disorder, post-traumatic stress disorder, chronic idiopathic pelvic pain, Gulf War Syndrome, vulvar vestibulitis, osteoarthritis, rheumatoid arthritis, and angina pectoris."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 5, wherein the somatosensory disorder comprises irritable bowel syndrome."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 5, wherein the somatosensory disorder comprises a chronic pain condition."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of Claim 5, wherein the somatosensory disorder comprises temporomandibular joint disorder."],"number":15,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}